Mast Therapeutics Inc (MSTX) 0.57 $MSTX
4 Biotech Stocks Under $10 to Watch for Breakout Trades
at The Street - Fri Jun 20, 7:27AM CDT
These biotech stocks trading for under $10 are starting to push higher into breakout territory.
Mast Announces names Dr Howard C Dittrich to board
M2 - Fri Jun 20, 4:03AM CDT
Biopharmaceutical company Mast Therapeutics (NYSE MKT:MSTX) revealed on Thursday the addition of Howard C Dittrich MD FACC, to its board of directors.
Mast Announces Appointment Of Howard C. Dittrich M.D. To Board of Directors
PR Newswire - Thu Jun 19, 3:15PM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that Howard C. Dittrich, M.D., F.A.C.C., has joined its Board of Directors. Dr. Dittrich, a cardiologist by training, has more than 20 years of experience in cardiac therapeutic research and clinical development.
Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial
PR Newswire - Mon Jun 16, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that, in line with prior guidance, it has initiated patient enrollment in a sub-study within EPIC, its pivotal phase 3 study of MST-188 in sickle cell disease, to investigate and quantify the effect of MST-188 on tissue oxygenation, which will be measured utilizing a non-invasive, FDA-approved device.
Technical Coverage on Active Stocks -- Research on Mast Therapeutics, North American Palladium, KeyCorp, and Synovus Financial
PR Newswire - Fri May 30, 7:30AM CDT
The trading session on Thursday, May 29, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,698.74, up 0.39% and the NASDAQ Composite closed at 4,247.95, up 0.54%. The S&P 500 finished the day 0.54% higher at 1,920.03. The gains were broad based as nine out of ten sectors finished on a positive note. Investor-Edge has initiated coverage on the following equities: Mast Therapeutics Inc. (NYSE MKT: MSTX), North American Palladium Ltd (NYSE MKT: PAL), KeyCorp (NYSE: KEY) and Synovus Financial Corp. (NYSE: SNV). Free technical research on MSTX, PAL, KEY and SNV can be downloaded upon signing up at:
5 Stocks Under $10 Set to Soar
at The Street - Thu May 29, 12:54PM CDT
These under-$10 stocks are within range of triggering breakout trades.
AmpliPhi Announces Appointment of New Board Member
Business Wire - Thu May 22, 3:15PM CDT
AmpliPhi BioSciences Corporation (OTCBB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that Wendy Johnson has been appointed to its Board of Directors effective May 19, 2014. Ms. Johnson will stand for election to the Board along with AmpliPhi's other Class 2 directors at the Company's Annual Meeting on June 27, 2014.
A Small-Cap Biotech Stock With Promise: MSTX
at The Street - Wed Mar 26, 1:55PM CDT
This small-cap biotech stock could be setting up for a great buying opportunity here following the massive selloff in the space.
Mast Therapeutics Reports Fourth Quarter And Full Year 2013 Financial Results
PR Newswire - Wed Mar 26, 7:15AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported financial results for the fourth quarter and year ended December 31, 2013.
Mast Therapeutics Initiates Phase 2 Study Of MST-188 In Patients With Acute Limb Ischemia
PR Newswire - Wed Mar 26, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) announced today that it has initiated a phase 2, clinical proof-of-concept study of MST-188 in combination with recombinant tissue plasminogen activator (rt-PA) in patients with acute lower limb ischemia. Acute limb ischemia (ALI), an acute complication of peripheral arterial disease, describes a sudden decrease in perfusion of a limb, typically in the legs, that often threatens viability of the limb. Patients presenting with ALI have a poor short-term outlook, with 30-day amputation rates as high as 30% and a mortality rate around 15%. MST-188 for the treatment of ALI has been granted orphan drug designation by the U.S. Food and Drug Administration.
Active Stocks Coverage -- Research on Starbucks, Gerdau, Mast Therapeutics and Cia de Saneamento Basico do Estado
PR Newswire - Fri Mar 21, 9:28AM CDT
The trading session on Thursday, March 20, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,331.05, up 0.67% and the NASDAQ Composite closed at 4,319.29, up 0.27%. The S&P 500 finished the session 0.60% higher at 1,872.01. The gains were broad based with 9 of 10 sectors ended the session in positive. Investor-Edge looks at some of the equities which traded the most shares during the session. These include FullStarbucks Corp. (NASDAQ: SBUX), Gerdau S.A. (NYSE: GGB), Mast Therapeutics Inc. (NYSE MKT: MSTX) and Cia de Saneamento Basico do Estado de Sao Paulo (NYSE: SBS). Free technical research on SBUX, GGB, MSTX and SBS can be downloaded upon signing up at:
Purified Poloxamer Granted Unique Nonproprietary Name (Vepoloxamer) By U.S. Adopted Names Council
PR Newswire - Tue Mar 11, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) announced today that the United States Adopted Names (USAN) Council has selected "vepoloxamer" as the unique non-proprietary (generic) name for the active pharmaceutical ingredient (API) in MST-188, the Company's lead product candidate. Mast sought a unique name for its API to clearly identify it as different from non-purified poloxamers. In support of its application, the Company argued that drug products containing non-purified poloxamers should not be substituted for MST-188 and that confusion between the two could have serious toxicity consequences.
Vista Partners Publishes March 2014 Macroeconomic & Investment Newsletter
Marketwire - Fri Mar 07, 8:00AM CST
Vista Partners ("Vista"
announced today that it published its FREE Macroeconomic & Investment Monthly Newsletter for the month of March. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary.
Vista Partners Updates Coverage on Mast Therapeutics, Inc. (NYSE MKT: MSTX); Price Target $2.25
Marketwire - Fri Feb 28, 8:00AM CST
Vista Partners announced today that it has updated coverage on Mast Therapeutics Inc. (NYSE MKT: MSTX) ("MSTX", a publicly traded biopharmaceutical company headquartered in San Diego, CA; and maintains its twelve-month price target of $2.25. Ross Silver, Principal Analyst at Vista Partners, stated, "There has been considerable partnership and M&A activity for companies working on Sickle Cell Disease. On Sept. 19th, 2012, Selexys Pharmaceuticals, Corp. entered into an agreement with Novartis Pharmaceuticals, the agreement with Novartis could reach up to $665 million. In October 2011, Pfizer signed a licensing deal with U.S. firm GlycoMimetics which may be worth up to $340 million, including an upfront payment as well as development, regulatory, and commercial milestones, plus royalties." Mr. Silver, concludes, "GlycoMimetics (NASDAQ: GLYC), the first biotech IPO of 2014, currently trades at a market cap of around $225M whereas MSTX is around $85M. GlycoMimetics has only completed a Phase 2 trial whereas MSTX is actively enrolling patients in a Phase 3 trial."
Mast Therapeutics acquires Aires Pharmaceuticals in all-stock transaction
M2 - Fri Feb 28, 3:43AM CST
Biopharmaceutical company Mast Therapeutics (NYSE MKT:MSTX) disclosed on Thursday the completion of the acquisition of Aires Pharmaceuticals in an all-stock transaction.
Mast Therapeutics Completes Acquisition Of Aires Pharmaceuticals, Inc.
PR Newswire - Thu Feb 27, 1:18PM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that it has completed its acquisition of Aires Pharmaceuticals, Inc. Aires' lead product candidate, AIR001, is an intermittently nebulized formulation of nitrite that has orphan drug designation in the U.S. and European Union for the treatment of pulmonary arterial hypertension.
Mast Therapeutics To Present At The Cowen & Co. 34th Annual Healthcare Conference On March 3rd
PR Newswire - Tue Feb 25, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Cowen & Co. 34th Annual Healthcare Conference on Monday, March 3, 2014 at 4:50 p.m. Eastern time at The Boston Marriott Copley Place Hotel in Boston.
Mast Therapeutics Announces International Expansion Of Phase 3 "EPIC" Study Of MST-188
PR Newswire - Mon Feb 24, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that, consistent with its prior guidance, it has initiated international enrollment in EPIC, its pivotal phase 3 study of MST-188 in sickle cell disease, with clinical sites now open in multiple foreign jurisdictions with high rates of hospitalization for sickle cell disease. The Company previously reported that it had met its goal of having 40 U.S. sites open by the end of 2013 and is on-track to opening an additional 30 sites outside of the U.S. by the end of 2014.
Mast Therapeutics Provides Additional Results From Nonclinical Heart Failure Study
PR Newswire - Tue Feb 18, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced new data from its randomized, placebo-controlled, nonclinical study of MST-188 (low dose and high dose) in a model of chronic heart failure.
4 Biotech Stocks Under $10 to Watch for Breakout Trades
at The Street - Fri Jun 20, 7:27AM CDT
These biotech stocks trading for under $10 are starting to push higher into breakout territory.
Mast Announces names Dr Howard C Dittrich to board
M2 - Fri Jun 20, 4:03AM CDT
Biopharmaceutical company Mast Therapeutics (NYSE MKT:MSTX) revealed on Thursday the addition of Howard C Dittrich MD FACC, to its board of directors.
Mast Announces Appointment Of Howard C. Dittrich M.D. To Board of Directors
PR Newswire - Thu Jun 19, 3:15PM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that Howard C. Dittrich, M.D., F.A.C.C., has joined its Board of Directors. Dr. Dittrich, a cardiologist by training, has more than 20 years of experience in cardiac therapeutic research and clinical development.
Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial
PR Newswire - Mon Jun 16, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that, in line with prior guidance, it has initiated patient enrollment in a sub-study within EPIC, its pivotal phase 3 study of MST-188 in sickle cell disease, to investigate and quantify the effect of MST-188 on tissue oxygenation, which will be measured utilizing a non-invasive, FDA-approved device.
Technical Coverage on Active Stocks -- Research on Mast Therapeutics, North American Palladium, KeyCorp, and Synovus Financial
PR Newswire - Fri May 30, 7:30AM CDT
The trading session on Thursday, May 29, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,698.74, up 0.39% and the NASDAQ Composite closed at 4,247.95, up 0.54%. The S&P 500 finished the day 0.54% higher at 1,920.03. The gains were broad based as nine out of ten sectors finished on a positive note. Investor-Edge has initiated coverage on the following equities: Mast Therapeutics Inc. (NYSE MKT: MSTX), North American Palladium Ltd (NYSE MKT: PAL), KeyCorp (NYSE: KEY) and Synovus Financial Corp. (NYSE: SNV). Free technical research on MSTX, PAL, KEY and SNV can be downloaded upon signing up at:
5 Stocks Under $10 Set to Soar
at The Street - Thu May 29, 12:54PM CDT
These under-$10 stocks are within range of triggering breakout trades.
AmpliPhi Announces Appointment of New Board Member
Business Wire - Thu May 22, 3:15PM CDT
AmpliPhi BioSciences Corporation (OTCBB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that Wendy Johnson has been appointed to its Board of Directors effective May 19, 2014. Ms. Johnson will stand for election to the Board along with AmpliPhi's other Class 2 directors at the Company's Annual Meeting on June 27, 2014.
A Small-Cap Biotech Stock With Promise: MSTX
at The Street - Wed Mar 26, 1:55PM CDT
This small-cap biotech stock could be setting up for a great buying opportunity here following the massive selloff in the space.
Mast Therapeutics Reports Fourth Quarter And Full Year 2013 Financial Results
PR Newswire - Wed Mar 26, 7:15AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported financial results for the fourth quarter and year ended December 31, 2013.
Mast Therapeutics Initiates Phase 2 Study Of MST-188 In Patients With Acute Limb Ischemia
PR Newswire - Wed Mar 26, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) announced today that it has initiated a phase 2, clinical proof-of-concept study of MST-188 in combination with recombinant tissue plasminogen activator (rt-PA) in patients with acute lower limb ischemia. Acute limb ischemia (ALI), an acute complication of peripheral arterial disease, describes a sudden decrease in perfusion of a limb, typically in the legs, that often threatens viability of the limb. Patients presenting with ALI have a poor short-term outlook, with 30-day amputation rates as high as 30% and a mortality rate around 15%. MST-188 for the treatment of ALI has been granted orphan drug designation by the U.S. Food and Drug Administration.
Active Stocks Coverage -- Research on Starbucks, Gerdau, Mast Therapeutics and Cia de Saneamento Basico do Estado
PR Newswire - Fri Mar 21, 9:28AM CDT
The trading session on Thursday, March 20, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,331.05, up 0.67% and the NASDAQ Composite closed at 4,319.29, up 0.27%. The S&P 500 finished the session 0.60% higher at 1,872.01. The gains were broad based with 9 of 10 sectors ended the session in positive. Investor-Edge looks at some of the equities which traded the most shares during the session. These include FullStarbucks Corp. (NASDAQ: SBUX), Gerdau S.A. (NYSE: GGB), Mast Therapeutics Inc. (NYSE MKT: MSTX) and Cia de Saneamento Basico do Estado de Sao Paulo (NYSE: SBS). Free technical research on SBUX, GGB, MSTX and SBS can be downloaded upon signing up at:
Purified Poloxamer Granted Unique Nonproprietary Name (Vepoloxamer) By U.S. Adopted Names Council
PR Newswire - Tue Mar 11, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) announced today that the United States Adopted Names (USAN) Council has selected "vepoloxamer" as the unique non-proprietary (generic) name for the active pharmaceutical ingredient (API) in MST-188, the Company's lead product candidate. Mast sought a unique name for its API to clearly identify it as different from non-purified poloxamers. In support of its application, the Company argued that drug products containing non-purified poloxamers should not be substituted for MST-188 and that confusion between the two could have serious toxicity consequences.
Vista Partners Publishes March 2014 Macroeconomic & Investment Newsletter
Marketwire - Fri Mar 07, 8:00AM CST
Vista Partners ("Vista"
announced today that it published its FREE Macroeconomic & Investment Monthly Newsletter for the month of March. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary. Vista Partners Updates Coverage on Mast Therapeutics, Inc. (NYSE MKT: MSTX); Price Target $2.25
Marketwire - Fri Feb 28, 8:00AM CST
Vista Partners announced today that it has updated coverage on Mast Therapeutics Inc. (NYSE MKT: MSTX) ("MSTX"
, a publicly traded biopharmaceutical company headquartered in San Diego, CA; and maintains its twelve-month price target of $2.25. Ross Silver, Principal Analyst at Vista Partners, stated, "There has been considerable partnership and M&A activity for companies working on Sickle Cell Disease. On Sept. 19th, 2012, Selexys Pharmaceuticals, Corp. entered into an agreement with Novartis Pharmaceuticals, the agreement with Novartis could reach up to $665 million. In October 2011, Pfizer signed a licensing deal with U.S. firm GlycoMimetics which may be worth up to $340 million, including an upfront payment as well as development, regulatory, and commercial milestones, plus royalties." Mr. Silver, concludes, "GlycoMimetics (NASDAQ: GLYC), the first biotech IPO of 2014, currently trades at a market cap of around $225M whereas MSTX is around $85M. GlycoMimetics has only completed a Phase 2 trial whereas MSTX is actively enrolling patients in a Phase 3 trial." Mast Therapeutics acquires Aires Pharmaceuticals in all-stock transaction
M2 - Fri Feb 28, 3:43AM CST
Biopharmaceutical company Mast Therapeutics (NYSE MKT:MSTX) disclosed on Thursday the completion of the acquisition of Aires Pharmaceuticals in an all-stock transaction.
Mast Therapeutics Completes Acquisition Of Aires Pharmaceuticals, Inc.
PR Newswire - Thu Feb 27, 1:18PM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that it has completed its acquisition of Aires Pharmaceuticals, Inc. Aires' lead product candidate, AIR001, is an intermittently nebulized formulation of nitrite that has orphan drug designation in the U.S. and European Union for the treatment of pulmonary arterial hypertension.
Mast Therapeutics To Present At The Cowen & Co. 34th Annual Healthcare Conference On March 3rd
PR Newswire - Tue Feb 25, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Cowen & Co. 34th Annual Healthcare Conference on Monday, March 3, 2014 at 4:50 p.m. Eastern time at The Boston Marriott Copley Place Hotel in Boston.
Mast Therapeutics Announces International Expansion Of Phase 3 "EPIC" Study Of MST-188
PR Newswire - Mon Feb 24, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that, consistent with its prior guidance, it has initiated international enrollment in EPIC, its pivotal phase 3 study of MST-188 in sickle cell disease, with clinical sites now open in multiple foreign jurisdictions with high rates of hospitalization for sickle cell disease. The Company previously reported that it had met its goal of having 40 U.S. sites open by the end of 2013 and is on-track to opening an additional 30 sites outside of the U.S. by the end of 2014.
Mast Therapeutics Provides Additional Results From Nonclinical Heart Failure Study
PR Newswire - Tue Feb 18, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced new data from its randomized, placebo-controlled, nonclinical study of MST-188 (low dose and high dose) in a model of chronic heart failure.
